The 2022 Tandem Meetings | Latest updates in next generation genetic medicines from the Tandem Meetings 2022
John DiPersio, MD, PhD, Washington University, St. Louis, MO, shares the main topics discussed at the ASTCT/ASGCT Joint Session on next generation genetic medicines held at this year’s Tandem Meetings. In this session, leading experts Luigi Naldini, MD, PhD, Carl June, MD, and Jennifer Doudna, PhD, spoke on lentiviral vectors for gene therapy, CAR-T therapy, and gene editing. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Transcript (edited for clarity)
Yeah, so, I’m really excited about that. This is a joint session of the ASTCT, and the ASGCT, and my colleague, Hans-Peter Kiem, and I have been running this session for five years and we want it to continue. We have the approval of both societies to continue it for another five years. And what we’ve done, we’ve tried to showcase the best in the world scientifically and translationally focused on gene therapy, immunotherapy, and stem cell transplantation...
Yeah, so, I’m really excited about that. This is a joint session of the ASTCT, and the ASGCT, and my colleague, Hans-Peter Kiem, and I have been running this session for five years and we want it to continue. We have the approval of both societies to continue it for another five years. And what we’ve done, we’ve tried to showcase the best in the world scientifically and translationally focused on gene therapy, immunotherapy, and stem cell transplantation. We’ve had great speakers in the past, and this year is a particularly exciting year because we have the founders, they were the ones that initiated a lot of the science that is at this meeting and is at the ASGCT in a month from now focused on the development and design of lentiviral vectors for gene therapy and the father of that field is Luigi Naldini, who will speak from Milan. Then, for the translational component, the leader and the founder in the world for CAR-T therapies is Carl June, and he’ll be speaking. And then most importantly, now in the age of gene editing and CRISPR, Jennifer Doudna, who just won the Nobel Prize for CRISPR, along with another investigator will be also speaking. We’ll hear the latest and greatest about gene editing and genetic manipulation, the latest and greatest with lentiviral vectors in gene therapy for patients with inherited diseases, and the latest and greatest about genetic manipulation of immune cells for the treatment of cancer.
Read more...
